Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$2.62 - $4.97 $25,102 - $47,617
-9,581 Reduced 7.82%
112,936 $389,000
Q3 2022

Nov 14, 2022

BUY
$3.46 - $6.0 $423,908 - $735,102
122,517 New
122,517 $435,000

Others Institutions Holding IKNA

About Ikena Oncology, Inc.


  • Ticker IKNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,257,500
  • Market Cap $56.9M
  • Description
  • Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...
More about IKNA
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.